GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bicycle Therapeutics PLC (FRA:50BA) » Definitions » EV-to-FCF

Bicycle Therapeutics (FRA:50BA) EV-to-FCF : 1.73 (As of Mar. 27, 2025)


View and export this data going back to 2019. Start your Free Trial

What is Bicycle Therapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Bicycle Therapeutics's Enterprise Value is €-263.60 Mil. Bicycle Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was €-152.66 Mil. Therefore, Bicycle Therapeutics's EV-to-FCF for today is 1.73.

The historical rank and industry rank for Bicycle Therapeutics's EV-to-FCF or its related term are showing as below:

FRA:50BA' s EV-to-FCF Range Over the Past 10 Years
Min: -81.81   Med: -6.33   Max: 2.05
Current: 1.55

During the past 8 years, the highest EV-to-FCF of Bicycle Therapeutics was 2.05. The lowest was -81.81. And the median was -6.33.

FRA:50BA's EV-to-FCF is ranked better than
57.35% of 415 companies
in the Biotechnology industry
Industry Median: 4.49 vs FRA:50BA: 1.55

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-03-27), Bicycle Therapeutics's stock price is €7.85. Bicycle Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was €-2.668. Therefore, Bicycle Therapeutics's PE Ratio (TTM) for today is At Loss.


Bicycle Therapeutics EV-to-FCF Historical Data

The historical data trend for Bicycle Therapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bicycle Therapeutics EV-to-FCF Chart

Bicycle Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-FCF
Get a 7-Day Free Trial -13.61 -83.58 -5.61 -4.50 -0.58

Bicycle Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.50 -7.55 -2.89 -3.35 -0.58

Competitive Comparison of Bicycle Therapeutics's EV-to-FCF

For the Biotechnology subindustry, Bicycle Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bicycle Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bicycle Therapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Bicycle Therapeutics's EV-to-FCF falls into.


';

Bicycle Therapeutics EV-to-FCF Calculation

Bicycle Therapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=-263.600/-152.663
=1.73

Bicycle Therapeutics's current Enterprise Value is €-263.60 Mil.
Bicycle Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-152.66 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bicycle Therapeutics  (FRA:50BA) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Bicycle Therapeutics's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=7.85/-2.668
=At Loss

Bicycle Therapeutics's share price for today is €7.85.
Bicycle Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.668.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Bicycle Therapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Bicycle Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Bicycle Therapeutics Business Description

Traded in Other Exchanges
Address
Granta Park, Great Abington, Blocks A and B, Portway Building, Cambridge, GBR, CB21 6GS
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.

Bicycle Therapeutics Headlines

No Headlines